Cardiovascular Intervention Research Center, Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Vali-Asr Ave, Tehran, Iran.
Clinical Trial Center, Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Int Urol Nephrol. 2019 Oct;51(10):1815-1822. doi: 10.1007/s11255-019-02235-w. Epub 2019 Jul 22.
Contrast-induced acute kidney injury (CI-AKI) is a serious complication in patients undergoing diagnostic cardiac angiography or percutaneous coronary intervention. We aimed to evaluate the preventive effects of left ventricular end-diastolic pressure (LVEDP)-guided hydration for the prevention of CI-AKI in patients with chronic kidney disease undergoing cardiac catheterization.
This prospective randomized single-blind clinical trial enrolled 114 eligible patients with an estimated glomerular filtration rate (eGFR) of 15 < eGFR ≤ 60 mL/min/1.73 m [according to the level-modified Modification of Diet in Renal Disease formula (MDRD)] and stable ischemic heart disease undergoing coronary procedures. The patients were randomly allocated 1:1 into the LVEDP-guided hydration group (n = 57) or the standard hydration group (n = 57). CI-AKI was defined as a greater than 25% or greater than 0.5 mg/dL (44.2 mmol/L) increase in the serum creatinine concentration compared with the baseline value. Hydration with 0.9% sodium chloride at a rate of 1 mL/kg/h (0.5 mL/kg/h if left ventricular ejection fraction < 40%) within 12 h was given to all the patients in both groups before the procedure. In the LVEDP-guided group, the hydration infusion rate was adjusted according to the LVEDP level during and after the procedure.
The incidence of CI-AKI was 7.01% (4/57) in the LVEDP-guided group vs 3.84% (2/52) in the standard hydration group (summary odds ratio 0.53, 95% CI 0.093-3.022; P = 0.463). Major adverse cardiac events, hemodialysis, or related deaths occurred in neither of the groups during hospitalization or the 30-day follow-up.
In the present study, LVEDP-guided fluid administration, by comparison with standard hydration, failed to offer protection against the risk of CI-AKI in patients with renal insufficiency undergoing coronary angiography with or without percutaneous coronary intervention.
对比剂诱导的急性肾损伤(CI-AKI)是接受诊断性心脏血管造影术或经皮冠状动脉介入治疗的患者的严重并发症。我们旨在评估左心室舒张末期压(LVEDP)指导的水化预防方案对接受心脏导管检查的慢性肾脏病患者 CI-AKI 的预防效果。
这是一项前瞻性随机单盲临床试验,纳入了 114 名估计肾小球滤过率(eGFR)为 15<eGFR≤60 mL/min/1.73 m²(根据水平修正的肾脏病膳食改良试验(MDRD)公式)且患有稳定型缺血性心脏病需行冠状动脉介入治疗的患者。患者按照 1:1 比例随机分为 LVEDP 指导的水化组(n=57)或标准水化组(n=57)。CI-AKI 的定义为与基线值相比血清肌酐浓度升高 25%或以上,或升高 0.5 mg/dL(44.2 mmol/L)或以上。两组患者在术前 12 小时内均给予 0.9%氯化钠以 1 mL/kg/h 的速度输注(如果左心室射血分数<40%,则为 0.5 mL/kg/h)。LVEDP 指导组根据术中及术后的 LVEDP 水平调整水化输注速度。
LVEDP 指导组的 CI-AKI 发生率为 7.01%(4/57),标准水化组为 3.84%(2/52)(汇总比值比 0.53,95%CI 0.093-3.022;P=0.463)。两组患者在住院期间或 30 天随访期间均未发生重大不良心脏事件、血液透析或相关死亡。
在本研究中,与标准水化相比,LVEDP 指导的液体管理并不能降低行冠状动脉造影术或同时行经皮冠状动脉介入治疗的肾功能不全患者发生 CI-AKI 的风险。